Please ensure Javascript is enabled for purposes of website accessibility

Why Teladoc’s Growth Story Is Just Getting Started

By Prosper Junior Bakiny – Jun 9, 2020 at 12:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Despite massive gains this year, the best may be yet to come for Teladoc.

Most industries have been hit hard by the ongoing crisis caused by the COVID-19 pandemic. For instance, the travel industry is struggling, and many travel companies will continue to face severe headwinds for the foreseeable future.

But other businesses are doing just fine, even flourishing amid the social distancing measures. The telehealth industry is an excellent example of this, and among the companies in this space, Teladoc (TDOC -3.46%) is one of the most prominent. Year to date, shares of this healthcare company are up by 93.1%, but there are good reasons to think Teladoc still has a lot of growth left in its engine. 

Telehealth services are here to stay

Teladoc generates revenue in two ways. First, the company charges per-visit fees for customers who use its services. Second, Teladoc charges fees to insurance companies that offer telehealth services to their clients as part of their policies. Obviously, the more insurance companies Teladoc can get on board, the better it is for its bottom line. And given recent events, it seems very likely that more and more insurance companies will look to offer telehealth services to their clients. 

A doctor on an iPad

Image Source: Getty Images

Specifically, hospitals have been busy dealing with COVID-19 patients, and to reserve resources for those suffering from the potentially deadly disease -- and to avoid unnecessary exposure to the virus on the part of the public -- many turned to telehealth services for some routine medical needs. Teladoc famously reported that its number of visits skyrocketed in March, and demand will likely remain high for a little while. These developments have boosted the profile of telehealth providers, leading many to conclude that people will seek to continue to have access to these services even after the pandemic subsides. 

Donna O'Shea, chief medical officer of population health management for UnitedHealthcare (one of the largest health insurance companies in the U.S.), certainly believes that. In a recent virtual conference called Telehealth's Tipping Point, O'Shea asserted that UnitedHealthcare's members will want to "continue to have access to their providers through telehealth."

This bodes well for the future of telehealth, and in particular for Teladoc, which remains the biggest player in this industry. 

Beware of these challenges 

Investing in Teladoc isn't without its risks; let's go over three things interested investors should consider before pulling the trigger.

First, there's the fact that the company isn't consistently profitable yet. During the first quarter, Teladoc posted a net loss of $29.6 million, a slight improvement compared to the net loss of $30.2 million the company recorded during the prior-year quarter. Of course, many growth stocks aren't consistently profitable, but it is something investors should keep in mind, especially given today's challenging economic conditions.

Second, there's the company's valuation. Due to its recent performance on the stock market, Teladoc's valuation metrics have gone through the roof. The company is currently trading for about 15.4 times its future sales. Third, of course there's competition. While many of Teladoc's competitors don't have much name recognition -- and probably don't pose a particularly strong challenge to Teladoc -- there's one competitor the company may have to worry about, namely Amazon (AMZN -0.12%)

Last year, the tech giant launched a virtual healthcare service called Amazon Care. So far, Amazon Care is reserved for Amazon's employees, but it seems likely that Amazon will eventually extend these services to the general public. Amazon could become one of Teladoc's biggest competitors in the years to come, and given the tech company's track record, it would likely be a formidable competitor to Teladoc. 

Teladoc is worth the premium

Even with the potential threat from Amazon, I think there's space for both Amazon and Teladoc in the telehealth market. This industry remains largely untapped, and given Teladoc's leading position in the industry, the company will likely be one of the biggest winners in the long run. After all, Teladoc has already managed to acquire a network of more than 50,000 clinicians worldwide, which allows the company to provide the convenient option of doctor visits 24 hours a day, seven days a week.

Competitors looking to knock Teladoc off its perch will have to accomplish (or rival) this difficult feat, while Teladoc continues to attract more customers, more healthcare professionals, and more insurance companies into its network. In short, I believe Teladoc will continue to beat the market long after COVID-19 is a thing of the past, which makes the company a buy. 

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Amazon and Teladoc Health. The Motley Fool recommends UnitedHealth Group and recommends the following options: short January 2022 $1940 calls on Amazon and long January 2022 $1920 calls on Amazon. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teladoc Health Stock Quote
Teladoc Health
$27.03 (-3.46%) $0.97
Amazon Stock Quote
$120.95 (-0.12%) $0.14
UnitedHealth Group Stock Quote
UnitedHealth Group
$527.07 (0.74%) $3.90

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.